A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring HRAS Mutations.

Hye Won LeeJason K SaAntonio GualbertoCatherine ScholzHyun Hwan SungByong Chang JeongHan Yong ChoiGhee Young KwonSe Hoon Park

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

Oral tipifarnib resulted in a manageable safety profile and encouraging antitumor efficacy against treatment-refractory urothelial carcinoma containing HRAS mutations.

Keyphrases

squamous cell carcinoma
small cell lung cancer
open label
combination therapy
newly diagnosed